Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...

Next-generation antibody company AnaptysBio has positive data for its lead pipeline drug etokimab in a third indication, adding asthma to its earlier wins in peanut allergy and atopic dermatitis ...

That said, etokimab will continue to lead the pipeline, and the latest interim data from the phase 2a study in eosinophilic asthma have given investors something to cheer about following the ...

Equally important to effectively improving the quality of life of asthma patients is the fact that etokimab didn't cause any serious adverse events, which bolsters its safety profile. Other ...

The oral presentation, titled “Single-Dose Phase 2a Trial of Etokimab (anti-IL-33) in Severe Eosinophilic Asthma”, was presented by Dr. Marco Londei, AnaptysBio’s Chief Medical Officer, and ...

Etokimab is also currently being trialled to treat eosinophilic asthma. Phase 2a clinical trial data testing the drug on that disorder were reported earlier in the year and demonstrated similar ...

After clearing a midstage study in asthma last fall, AnaptysBio’s anti-IL-33 antibody missed the mark in a phase 2b trial testing it in atopic dermatitis, or eczema. The drug, etokimab, did ...

The biopharma announced positive top-line data from a phase 2a trial involving its lead drug candidate as a treatment for asthma.

Equally important to effectively improving the quality of life of asthma patients is the fact that etokimab didn't cause any serious adverse events, which bolsters its safety profile. Other ...

Shares of AnaptysBio (NASDAQ: ANAB) rose over 18% after the company announced positive top-line data from an ongoing phase 2a trial investigating the potential of its lead drug candidate to treat ...

What happened Shares of AnaptysBio (NASDAQ: ANAB) rose more than 12% last month, according to data provided by S&P Global Market Intelligence ..

What happened Shares of AnaptysBio (NASDAQ: ANAB) rose over 18% after the company announced positive top-line data from an ongoing phase 2a trial.